Continuous infusion of selective dopamine uptake inhibitors or cocaine produces time-dependent changes in rat locomotor activity

Behavioural Brain Research

Volumn 99, Issue 2, 1999, Pages 201-208

  Izenwasser, Sari ^a   French, Dawn ^a   Carroll, F Ivy ^b   Kunko, Paul M ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b RTI INTERNATIONAL   (United States)

Author keywords

Cocaine; Continuous administration; Dopamine; GBR 12909; Locomotion; Norepinephrine; Serotonin; Transporters

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID ISOPROPYL ESTER; COCAINE; DOPAMINE UPTAKE INHIBITOR; FLUOXETINE; NISOXETINE; VANOXERINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DOPAMINE UPTAKE; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; DRUG EFFECT; LOCOMOTION; NEUROTRANSMITTER RELEASE; NONHUMAN; NORADRENALIN RELEASE; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT; SENSITIZATION; SEROTONIN RELEASE;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; COCAINE; DOPAMINE UPTAKE INHIBITORS; DRUG TOLERANCE; FLUOXETINE; INFUSION PUMPS, IMPLANTABLE; MALE; MONOAMINE OXIDASE INHIBITORS; MOTOR ACTIVITY; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 0032912598     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(98)00104-1     Document Type: Article

References (37)

1. Andersen P.H. The dopamine uptake inhibitor GBR 12909: selectivity and molecular mechanism of action. Eur J Pharmacol. 166:1989;493-504.
2. Baumann M.H., Char G.U., Costa B.R.D., Rice K.C., Rothman R.B. GBR 12909 attenuates cocaine-induced activation of mesolimbic dopamine neurons in the rat. J Pharmacol Exp Ther. 271:1994;1216-1222.
3. 3H]GBR 12935: a specific high affinity ligand for labeling the dopamine transport complex. Eur J Pharmacol. 107:1985;289-290.
4. 3H]GBR 12935 and GBR 12909 with the dopamine uptake complex in nucleus accumbens. Eur J Pharmacol. 177:1990;91-94.
5. 3H]GBR 12783 binding to a specific site associated with the neuronal dopamine uptake complex in the central nervous system. Eur J Pharmacol. 126:1986;211-222.
6. Carroll F.I., Kotian P., Dehghani A., Gray J.L., Kuzemko M.A., Parham K.A., Abraham P., Lewin A.H., Boja J.W., Kuhar M.J. Cocaine and 3beta-(4′-substituted phenyl)tropane-2beta-carboxylic acid ester and amide analogues. new high-affinity and selective compounds for the dopamine transporter. J Med Chem. 38:1995;379-388.
7. Chen N.-H., Reith M.E.A. Dopamine and serotonin release-regulating autoreceptor sensitivity in A9/A10 cell body and terminal areas after withdrawal of rats from continuous infusion of cocaine. J Pharmacol Exp Ther. 267:1993;1445-1453.
8. Chen N.-H., Reith M.E.A. Monoamine interactions measured by microdialysis in the ventral tegmental area of rats treated systemically with (±)-8-hydroxy-2-(di-n-propylamino)tetralin. J Neurochem. 64:1995;1585-1597.
9. Durcan M.J., Lister R.G., Eckardt M.J., Linnoila M. Behavioral interactions of fluoxetine and other 5-hydroxytryptamine uptake inhibitors with ethanol in tests of anxiety, locomotion and exploration. Psychopharmacology. 96:1988;528-533.
10. Fleckenstein A.E., Kopajtic T.A., Boja J.W., Carroll F.I., Kuhar M.J. Highly potent cocaine analogs cause long-lasting increases in locomotor activity. Eur J Pharmacol. 311:1996;109-114.
11. French D., Izenwasser S. Tolerance and sensitization to cocaine are mediated via independent mechanisms. Soc Neurosci Abstr. 22:1996;921.
12. Heron C., Costentin J., Bonnet J.-J. Evidence that pure uptake inhibitors including cocaine interact slowly with the dopamine neuronal carrier. Eur J Pharmacol. 264:1994;391-398.
13. Inada T., Polk K., Purser C., Hume A., Hoskins B., Ho I.K., Rockhold R.W. Behavioral and neurochemical effects of continuous infusion of cocaine in rats. Neuropharmacology. 31:1992;701-708.
14. Izenwasser S. Increased mu-opioid efficacy for inhibition of adenylyl cyclase induced by chronic treatment with naltrexone or cocaine. Regul Pept. 54:1994;131.
15. Izenwasser S. Interactions between chronic cocaine and morphine on locomotor activity and dopamine receptor function. Soc Neurosci Abstr. 21(1):1995;717.
16. Izenwasser S., Cox B.M. Inhibition of dopamine uptake by cocaine and nicotine: tolerance to chronic treatments. Brain Res. 573:1992;119-125.
17. Johansson E.K., Tucker S.M., Ginn H.B., Martin B.R., Aceto M.D. Functional and dispositional tolerance develops during continuous cocaine exposure. Eur J Drug Metab Pharmacokinet. 17:1992;155-162.
18. Kalivas P.W., Duffy P., DuMars L.A., Skinner C. Behavioral and neurochemical effects of acute and daily cocaine administration in rats. J Pharmacol Exp Ther. 245:1988;485-492.
19. King G.R., Joyner C., Lee T., Kuhn C., Ellinwood E.H. Jr. Intermittent and continuous cocaine administration: Residual behavioral states during withdrawal. Pharmacol Biochem Behav. 43:1992;243-248.
20. 2 receptor function. J Pharmacol Exp Ther. 269:1994;743-749.
21. Kunko P.M., Carroll F.I., Izenwasser S. Chronic continuous administration of monoamine uptake inhibitors produces behavioral tolerance but not a cocaine-like activity pattern. Soc Neurosci Abstr. 22:1996;920.
22. Kunko P.M., Carroll F.I., Izenwasser S. Tolerance to the inhibition of dopamine uptake by cocaine following chronic treatment with GBR 12909. NIDA Res Monogr. 174:1997;229.
23. Kunko P.M., Loeloff R.J., Izenwasser S. Chronic administration of GBR 12909, but not cocaine, produces marked decreases in dopamine transporter density. Naunyn-Schmiedeberg's Arch Pharmacol. 356:1997;562-569.
24. Kunko P.M., French D., Izenwasser S. Alterations in locomotor activity during chronic cocaine administration: Effect on dopamine receptors and interaction with opioids. J Pharmacol Exp Ther. 285:1998;277-284.
25. Kunko PM, Ladenheim B, Cadet JL, Carroll FI, Izenwasser S. Reductions in dopamine transporter and D1 receptor binding after chronic GBR 12909. NIDA Res Monogr Problems Drug Dependence, 1998;178:272.
26. 1 agonist RU 24969 and effects on dopaminergic behavior. Eur J Pharmacol. 139:1987;205-214.
27. 3H]WIN 35 428 binding to dopamine uptake sites in vivo more rapidly than mazindol or GBR 12909. Eur J Pharmacol. 198:1991;203-205.
28. 3H]cocaine in mouse striatum and cerebral cortex have different dissociation kinetics. J Neurochem. 46:1986;309-312.
29. Reith M.E.A., Benuck M., Lajtha A. Cocaine disposition in the brain after continuous or intermittent treatment and locomotor stimulation in mice. J Pharmacol Exp Ther. 243:1987;281-287.
30. Reith M.E.A., de Costa B., Rice K.C., Jacobson A.E. Evidence for mutually exclusive binding of cocaine, BTCP, GBR 12935, and dopamine to the dopamine transporter. Eur J Pharmacol-Mol Pharmacol Section. 227:1992;417-425.
31. 1B receptor activation mimics behavioral effects of presynaptic serotonin release. Neuropsychopharmacology. 8:1993;201-211.
32. Rothman R.B., Mele A., Reid A.A., Akunne H.C., Greig N., Thurkauf A., Costa B.R.D., Rice K.C., Pert A. GBR 12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine. Pharmacol Biochem Behav. 40:1991;387-397.
33. Rothman R.B., Greig N., Kim A., Costa B.R.D., Rice K.C., Carroll F.I., Pert A. Cocaine and GBR 12909 produce equivalent motoric responses at different occupancy of the dopamine transporter. Pharmacol Biochem Behav. 43:1992;1135-1142.
34. Saadouni S., Refahi-Lyamani F., Costentin J., Bonnet J.-J. Cocaine and GBR 12783 recognize nonidentical, overlapping binding domains on the dopamine neuronal carrier. Eur J Pharmacol. 268:1994;187-197.
35. Segal D.S., Kuczenski R. Repeated cocaine administration induces behavioral sensitization and corresponding decreased extracellular dopamine responses in caudate and accumbens. Brain Res. 577:1992;351-355.
36. Stathis M., Scheffel U., Lever S.Z., Boja J.W., Carroll F.I., Kuhar M.J. Rate of binding of various inhibitors at the dopamine transporter in vivo. Psychopharmacology. 119:1995;376-384.
37. Tella S.R. Possible novel pharmacodynamic action of cocaine: cardiovascular and behavioral evidence. Pharmacol Biochem Behav. 54:1996;343-354.